55yo patient with de-novo metastatic (bone) HR+/HER2- MBC. Received letrozole + ribociclib for 2 years, at which point she develops liver progression of disease. ctDNA shows an ESR1 mutation, all the rest wild type.
What next treatment would you choose, assuming all available?